Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
$3.07
+1.7%
$2.81
$1.78
$8.56
$63.37M0.9277,460 shs34,937 shs
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
$15.25
$15.23
$4.81
$15.37
$753.61M-0.06974,748 shs600 shs
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
$9.90
+0.3%
$9.71
$2.20
$12.78
$270.39M-0.3632,815 shs72,334 shs
Mesoblast Limited stock logo
MESO
Mesoblast
$15.46
+4.3%
$14.57
$6.00
$22.00
$1.90B2.26219,601 shs162,435 shs
Vericel Corporation stock logo
VCEL
Vericel
$31.42
-2.4%
$36.54
$30.26
$63.00
$1.62B1.33669,483 shs1.22 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
0.00%-14.20%+5.59%+22.27%-58.23%
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
0.00%+8.46%-1.20%+3.35%+172.01%
Mesoblast Limited stock logo
MESO
Mesoblast
0.00%+2.99%-8.80%+20.49%+138.26%
Vericel Corporation stock logo
VCEL
Vericel
0.00%-5.49%-11.30%-22.63%-29.85%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
$3.07
+1.7%
$2.81
$1.78
$8.56
$63.37M0.9277,460 shs34,937 shs
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
$15.25
$15.23
$4.81
$15.37
$753.61M-0.06974,748 shs600 shs
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
$9.90
+0.3%
$9.71
$2.20
$12.78
$270.39M-0.3632,815 shs72,334 shs
Mesoblast Limited stock logo
MESO
Mesoblast
$15.46
+4.3%
$14.57
$6.00
$22.00
$1.90B2.26219,601 shs162,435 shs
Vericel Corporation stock logo
VCEL
Vericel
$31.42
-2.4%
$36.54
$30.26
$63.00
$1.62B1.33669,483 shs1.22 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
0.00%-14.20%+5.59%+22.27%-58.23%
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
0.00%+8.46%-1.20%+3.35%+172.01%
Mesoblast Limited stock logo
MESO
Mesoblast
0.00%+2.99%-8.80%+20.49%+138.26%
Vericel Corporation stock logo
VCEL
Vericel
0.00%-5.49%-11.30%-22.63%-29.85%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
2.75
Moderate Buy$19.75543.32% Upside
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
0.00
N/AN/AN/A
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
2.80
Moderate Buy$14.7548.99% Upside
Mesoblast Limited stock logo
MESO
Mesoblast
3.20
Buy$18.0016.43% Upside
Vericel Corporation stock logo
VCEL
Vericel
3.00
Buy$60.4092.23% Upside

Current Analyst Ratings Breakdown

Latest ADVM, VCEL, DBVT, AERI, and MESO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/13/2025
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$33.00
8/5/2025
Mesoblast Limited stock logo
MESO
Mesoblast
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/1/2025
Vericel Corporation stock logo
VCEL
Vericel
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$61.00 ➝ $58.00
7/18/2025
Mesoblast Limited stock logo
MESO
Mesoblast
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyHold
6/26/2025
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$16.00 ➝ $12.00
6/26/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
Lifesci Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
6/26/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
JMP Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform$21.00
6/16/2025
Vericel Corporation stock logo
VCEL
Vericel
Stephens
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$67.00
(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
$1M64.41N/AN/A$3.40 per share0.90
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
$194.13M3.88N/AN/A($3.32) per share-4.59
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
$4.15M65.36N/AN/A$1.42 per share6.97
Mesoblast Limited stock logo
MESO
Mesoblast
$17.20M115.05N/AN/A$4.67 per share3.31
Vericel Corporation stock logo
VCEL
Vericel
$237.22M6.68$0.31 per share102.98$5.92 per share5.31
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
-$130.93M-$7.85N/AN/AN/AN/A-297.29%-101.40%11/3/2025 (Estimated)
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
-$74.81M-$0.77N/AN/AN/A-17.09%N/A-2.00%N/A
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
-$113.92M-$4.77N/AN/AN/A-3,220.49%-287.15%-138.83%11/5/2025 (Estimated)
Mesoblast Limited stock logo
MESO
Mesoblast
-$102.14MN/A0.00N/AN/AN/AN/AN/AN/A
Vericel Corporation stock logo
VCEL
Vericel
$10.36M$0.12261.8671.41N/A2.85%2.47%1.69%11/6/2025 (Estimated)

Latest ADVM, VCEL, DBVT, AERI, and MESO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
-$2.24-$2.34-$0.10-$2.34N/AN/A
7/31/2025Q2 2025
Vericel Corporation stock logo
VCEL
Vericel
-$0.04-$0.01+$0.03-$0.01$64.61 million$63.24 million
7/29/2025Q2 2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
-$0.21-$1.55-$1.34-$1.55$0.64 million$1.74 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
N/AN/AN/AN/AN/A
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
N/AN/AN/AN/AN/A
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
N/AN/AN/AN/AN/A
Mesoblast Limited stock logo
MESO
Mesoblast
N/AN/AN/AN/AN/A
Vericel Corporation stock logo
VCEL
Vericel
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
N/A
1.54
1.54
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
N/A
2.27
1.92
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
N/A
2.45
2.45
Mesoblast Limited stock logo
MESO
Mesoblast
0.11
1.99
1.77
Vericel Corporation stock logo
VCEL
Vericel
N/A
4.97
4.56

Institutional Ownership

CompanyInstitutional Ownership
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
48.17%
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
95.94%
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
71.74%
Mesoblast Limited stock logo
MESO
Mesoblast
1.43%
Vericel Corporation stock logo
VCEL
Vericel
N/A

Insider Ownership

CompanyInsider Ownership
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
6.00%
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
4.44%
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
1.44%
Mesoblast Limited stock logo
MESO
Mesoblast
18.80%
Vericel Corporation stock logo
VCEL
Vericel
7.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
19020.98 million19.73 millionOptionable
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
37649.42 million47.22 millionOptionable
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
8027.40 million27.00 millionOptionable
Mesoblast Limited stock logo
MESO
Mesoblast
80128.00 million103.93 millionOptionable
Vericel Corporation stock logo
VCEL
Vericel
30050.46 million46.83 millionOptionable

Recent News About These Companies

Vericel (NASDAQ:VCEL) Shares Down 5.8% - Here's Why
Here’s Why Vericel Corp. (VCEL) Traded Down in Q2

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adverum Biotechnologies stock logo

Adverum Biotechnologies NASDAQ:ADVM

$3.07 +0.05 (+1.66%)
Closing price 04:00 PM Eastern
Extended Trading
$3.08 +0.01 (+0.16%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Aerie Pharmaceuticals stock logo

Aerie Pharmaceuticals NASDAQ:AERI

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.

DBV Technologies stock logo

DBV Technologies NASDAQ:DBVT

$9.79 -0.08 (-0.80%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Mesoblast stock logo

Mesoblast NASDAQ:MESO

$15.46 +0.64 (+4.32%)
Closing price 04:00 PM Eastern
Extended Trading
$15.86 +0.40 (+2.55%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Vericel stock logo

Vericel NASDAQ:VCEL

$31.42 -0.76 (-2.36%)
Closing price 04:00 PM Eastern
Extended Trading
$31.42 -0.01 (-0.02%)
As of 04:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.